High expression of COMMD6 correlates with shorter survival in HNSC, CHOL, ACC patients and longer survival in LGG, UVM, TGCT, THCA and UCEC patients, indicating that the expression of COMMD6 may be helpful in understanding the pathological mechanism and providing new diagnostic and therapeutic biomarkers for these tumours. This evidence concerns the gene COMMD6 and adrenal cortex carcinoma.